TPWM
DFTX

Twelve Points Wealth Management’s Definium Therapeutics DFTX Stock Holding History

Twelve Points Wealth Management’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$670K Buy
14,245
+2,000
+16% +$49.4K 0.13% 123
2026
Q1 		$231K Buy
12,245
+1,600
+15% +$27.2K 0.05% 179
2025
Q4 		$147K Buy
+10,645
New +$132K 0.03% 192

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Twelve Points Wealth Management's DFTX Position: Q2 2026 in Review

Twelve Points Wealth Management increased its Definium Therapeutics (DFTX) stake by 16% in Q2 2026, buying an estimated $49.4K and bringing the position to 14,245 shares worth $670K. The position accounts for 0.13% of the portfolio, ranked #123.

Twelve Points Wealth Management first reported a position in DFTX in Q4 2025 and has held it in 3 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Twelve Points Wealth Management held 14,245 shares of Definium Therapeutics worth $670K as of Q2 2026.
  • Twelve Points Wealth Management bought 2,000 Definium Therapeutics shares in Q2 2026, an estimated $49.4K.
  • Definium Therapeutics made up 0.13% of Twelve Points Wealth Management's portfolio in Q2 2026, its #123 holding.
  • Twelve Points Wealth Management first reported a position in Definium Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Twelve Points Wealth Management's 13F filing for Q2 2026, filed 7 Aug 2026.